



1 / 45

Figure 1




2 / 45

Figure 2




3 / 45

Figure 3




4 / 45

Figure 4




5 / 45

Figure 5




6 / 45

Figure 6




7 / 45

Figure 7




8 / 45

Figure 8




9 / 45

Figure 9




10 / 45

Figure 10




11 / 45

Figure 11



12 / 45


Figure 12
Dextromethorphan HBr Dissolution Release Rates for Mucinox DM
1200 mg Guaifonesin / 60 mg Dextromethorphan HBr (Mean, Standard Error)



13 / 45

Figure 13


Guaifenesin Plasma Concentrations Following the Administration of 1200 mg Guaifenesin and 60 mg Dextromethorphan Hydrobromide to Normal Volunteers in Three Formulations (Mean, Standard Error)



14/ 45

Figure 14


Dextromethorphan Plasma Concentrations Following the Administration of 1200 mg Guaifenesin and 60 mg Dextromethorphan Hydrobromide to Normal Volunteers in Three Formulations (Mean, Standard Error)



15 / 45

Figure 15


Dextrophan Plasma Concentrations Following the Administration of 1200 mg Guafenesin and 60 mg Dextromethorphan Hydrobromide to Normal Volunteers in Three Formulations (Mean, Standard Error)



16 / 45

Figure 16


Pseudoephedrine HCl Dissolution Release Rates for Mucinex D
1200 mg Guaifenesin/ 120 mg Pseudoephedrine HCl



17 / 45

Figure 17


Plasma Guaifenesin Concentration Following Administration of 1200 mg Guaifenesin Along with 120 mg Pseudoephedrine HCl to Normal Volunteers (Mean, Standard Error)



18 / 45

Figure 18


Plasma Pseudoephedrine Concentration Following Administration of 120 mg Pseudoephedrine HCl along with 1200 mg Guaifenesin to Normal Volunteers (Mean, Standard Error)



19 / 45

Figure 19


Plasma Gualifenesin Concentrations Following the Administration of 1200 mg Gualifenesin in
Three Different Formulations to Normal Volunteers
(Mean, Standard Error)



20 / 45

Figure 20


Pseudoephedrine Plasma Concentration Following the Administration of 1200 mg Guafenesin and 120 mg Pseudoephedrine Hydrochloride to Normal Volunteers in Three Different Formulations (Mean, Standard Error)



21 / 45

Figure 21


Plasma Guaifenesin Concentrations Following the Administration of Guaifenesin in Different Formulations and Different Doses to Normal Volunteers (Mean, Standard Error)



22 / 45

Figure 22


Plasma Pseudoephedrine Concentrations Following the Administration of Two Different Dose Strengths of Pseudoephedrine Hydrochloride as well as Different Formulations to Normal Volunteers



23 / 45

Figure 23


Plasma Guaifenesin Concentrations Following the Administration of 1200 mg Guaifenesin
Along with 120 mg Pseudoephedrine Hydrochloride in Two Different Formulations
Following the Consumption of a High-Fat Meal
(Mean, Standard Error)



24 / 45

Figure 24


Plasma Pseudoephedrine Concentrations Following a Dose of 120 mg Pseudoephedrine Hydrochloride Administered in Two Different Formulations Following the Consumption of a High-Fat Meal (Mean, Standard Error)



25 / 45

Figure 25


Steady-State Plasma Gualfenesin Concentrations Following the Administration of 11 Doses of 1200 mg Gualfenesin along with 120 mg Pseudoephedrine Hydrochloride in 2 Different Formulations to Normal Volunteers (Mean, Standard Error)



26 / 45

Figure 26


Steady-State Plasma Pseudoephedrine Concentrations Following the Administration of 11 Doses of 120 mg Pseudoephedrine Hydrochloride Along with 1200 mg of Guafenesin in 2 Different Formulations to Normal Volunteers (Mean, Standard Error)



27 / 45

Figure 27


Plasma Guafenesin Concentrations Following the Administration of 1200 mg Guafenesin
with or without the Coadministration of 120 mg Pseudoephedrine Hydrochloride in Normal
Volunteers



28 / 45

Figure 28


Plasma Pseudoephedrine Concentrations Following the Administration of 120 mg Pseudoephedrine Hydrochloride to Normal Volunteers with or without the Coadministration of 1200 mg Guafenesin (Mean, Standard Error)



29 / 45

Figure 29


Plasma Guaifenesin Concentrations Following the Administration of 1200 mg Guaifenesin and 120 mg Pseudoephedrine Hydrochloride in an Experimental Formulation to Normal Volunteers Under Fed and Fasted Conditions
(Mean, Standard Error)



30 / 45


Figure 30

Plasma Pseudoephedrine Concentrations Following the Administration of 120 mg of Pseudoephedrine Hydrochloride and 1200 mg Guaifenesin in an Experimental Formulation to Normal Volunteers Under Fed and Fasted Conditions (Mean, Standard Error)



31 / 45


Figure 31



Mucinex™ D mean guaifenesin dissolution profiles for various clinical batches used in the bioavailability studies with associated dissolution specifications.

32 / 45

Figure 32




Mucinex™ D mean pseudoephedrine HCL dissolution profiles for various clinical batches used in the bioavailability studies with associated dissolution specifications.

33 / 45

Figure 33


Guaifenesin Plasma Concentrations Following the Administration of 1200 mg Guaifenesin with or without the Co-Administration of 60 mg Dextromethorphan Hydrobromide to Normal Volunteers (Mean, Standard Error)



34 / 45

Figure 34


Mean Dextromethorphan Plasma Concentrations Following the Administration of Dextromethorphan Hydrobromide in Different Formulations, Doses and Dosing Regimens



35 / 45

Figure 35


Plasma Guaifenesin Concentrations Following the Administration of 1200 mg Guaifenesin Along with 60 Dextromethorphan Hydrobromide in Three Different Formulations to Normal Volunteers (Mean, Standard Error)



36 / 45

Figure 36


Dextromethorphan Plasma Concentrations Following the Administration of 60 mg Dextromethorphan Hydrobromide at Three Different Rates to Normal Volunteers (Mean, Standard Error)



37 / 45

Figure 37


Plasma Gualfenesin Concentrations Following the Administration of 1200 mg Gualfenesin and 60 mg Dextromethorphan in an Experimental Formulation to Normal Volunteers Under Fed and Fasted Conditions
(Mean, Standard Error)



38 / 45

Figure 38


Plasma Dextromethorphan Concentrations Following the Administration of 60 mg Dextromethorphan Hydrobromide and 1200 mg Guaifenesin to Normal Volunteers in the Fed and Fasted Conditions (Mean, Standard Error)



39 / 45


Figure 39

Steady-State Plasma Concentrations of Gualfenesin Following the Multiple Dose Administration of 1200 mg Gualfenesin in Different Formulations to Normal Volunteers. (Mean, Standard Error)



40 / 45


Figure 40

Mean Steady-State Guaifenesin Plasma Concentration-Time Profiles

41 / 45

Figure 41


Steady-State Plasma Concentrations of Dextromethorphan Following the Multiple Dose Administration of 60 mg Dextromethorphan Hydrobromide in Different Formulations and/or Different Dosing Rates to Normal Volunteers:
(Mean, Standard Error)




42 / 45

Figure 42

Dextromethorphan Plasma Concentrations Following the Administration of 60 mg Dextromethorphan Hydrobromide in Different Formulations and Dosage Rates to Normal Volunteers




43 / 45

Figure 43**Process Flow Diagram for the Manufacture of Guafenesin DC (95%)**

44 / 45

Figure 44

Process Flow Diagram for Guaifenesin/Pseudoephedrine (1200/120mg Tablets)



45 / 45

Figure 45

Process Flow Diagram for Guaifenesin/Pseudoephedrine (600/60mg Tablets)

